Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.

Journal of hematology & oncology - 21 Nov 2019

Li Boheng, Chng Wee-Joo

Abstract excerpt

EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which along with other PRC2 components mediates gene expression suppression via the methylation of Histone H3 at lysine 27. Recent studies have revealed a dichotomous role of EZH2 in physiology and in the pathogenesis of cancer. While it plays an essential role in the development of the lymphoid system, its deregulation, whether due to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Enhancer of Zeste Homolog 2 Protein
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Lymphoma

Share to Polycomb Repressive Complex 2

Share to Protein Processing, Post-Translational

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 31752930
DOI: 10.1186/s13045-019-0814-6
PMCID: PMC6868783

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.PMID 31752930Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.Semantic proximity Read ↗

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.Semantic proximity Read ↗

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancerSemantic proximity Read ↗

Overexpression of enhancer of zests homolog 2 in lymphoma.Semantic proximity Read ↗

Targeting EZH2 in cancer.Semantic proximity Read ↗

EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphomaSemantic proximity Read ↗

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.Semantic proximity Read ↗

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.Semantic proximity Read ↗

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read ↗

AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.